Ultragenyx Pharma Misses Q1 EPS by 43c
- ByInvesting.com-
Ultragenyx Pharma (RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus...
Symbol | Exchange | Currency |
|---|
Ultragenyx Pharma (RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus...
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) on Monday, setting a price target of $178, which is approximately...
Robert W. Baird analyst Joel Beatty maintained a Hold rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) on Monday, setting a price target of $109, which is approximately 27.56%...
Businesses led by their founders receive significant attention on Wall Street and in academia. For instance, according to research by Bain & Co. published in Harvard Business...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN recently announced a license and collaboration agreement with Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc. RARE. Per the deal,...
Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc. (RARE) announced that the FDA has granted Orphan Drug Designation to UX701 for the treatment of Wilson disease. Wilson disease is a...
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 146.11 | 146.25 | 143.40 | +2.32 | +1.61% | 5.86M | NYSE | |||
| 52.31 | 52.37 | 51.25 | -0.12 | -0.23% | 16.06M | NYSE | |||
| 26.76 | 27.02 | 24.61 | +1.98 | +7.99% | 1.02M | NASDAQ | |||
| 151.31 | 151.45 | 148.21 | +4.04 | +2.74% | 47.44K | NASDAQ | |||
| 73.67 | 75.45 | 72.69 | -2.80 | -3.66% | 87.36M | NASDAQ | |||
| 7.77 | 8.01 | 7.64 | +0.07 | +0.91% | 7.04M | NASDAQ | |||
| 101.18 | 102.50 | 99.53 | -1.02 | -1.00% | 7.59M | NYSE | |||
| 116.00 | 116.63 | 112.92 | +2.32 | +2.04% | 16.68M | NYSE | |||
| 168.20 | 169.15 | 164.05 | +3.16 | +1.91% | 4.49M | NYSE | |||
| 155.05 | 156.24 | 154.74 | -0.69 | -0.44% | 309.27K | NASDAQ | |||
| 169.39 | 169.52 | 165.76 | +2.73 | +1.64% | 3.87M | NASDAQ | |||
| 110.22 | 110.47 | 107.65 | +1.57 | +1.45% | 3.24M | NYSE | |||
| 5.45 | 5.75 | 5.30 | -0.11 | -1.98% | 11.86K | NASDAQ | |||
| 74.60 | 74.82 | 71.12 | +4.03 | +5.71% | 3.52M | NYSE | |||
| 146.09 | 149.52 | 143.34 | -1.94 | -1.31% | 2.52M | NASDAQ |